The potential role of antibodies and T lymphocytes in the eradication of cancer has been demonstrated in numerous animal models and clinical trials. In the last decennia new strategies have been developed for the use of tumor-speciWc T cells and antibodies in cancer therapy. EVective anti-tumor immunotherapy requires the identiWcation of suitable target antigens. The expression of tumorspeciWc antigens has been extensively studied for most types of adult tumors. Pediatric patients should be excellent candidates for immunotherapy since their immune system is more potent and Xexible as compared to that of adults. So far, these patients do not beneWt enough from the progresses in cancer immunotherapy, and one of the reasons is the paucity of tumor-speciWc antigens identiWed on pediatric tumors. In this review we discuss the current status of cancer immunotherapy in children, focusing on the identiWcation of tumor-speciWc antigens on pediatric solid tumors.
Introduction
Despite major advances in the treatment of childhood malignancies, cancer remains in the developed world the second most common cause of death for children >1 year of age [76] . Children and adolescents with primary multifocal, refractory, or relapsed malignant solid tumors still have a poor prognosis. Moreover, most cancer therapies are associated with signiWcant toxicity leading to long-term morbidity and an increased second malignancy rate [75, 135] . Therefore, new treatment strategies are warranted. One of them is immunotherapy, in which the patient's own immune system is mobilized to Wght the cancer in a speciWc way, thereby causing only mild toxicity [101] .
The immune system can reject tumors
Early studies in mice showed that the immune system can recognize and reject tumors [39] . Numerous mouse tumor models have been developed to identify which part of the immune system is responsible for the eradication of tumors. These studies indicate that both CD8 + and CD4 + T cells play a critical role in tumor rejection or in inhibition of tumor growth [13] . The cytolytic activity of CD8 + T cells exerts a direct anti-tumor eVect [66] . CD4 + T cells participate through the activation and maintenance of CD8 + T cells and the recruitment of inXammatory cells such as macrophages, granulocytes, natural killer (NK) cells, and B cells [24, 47, 51, 93, 131] .
Tumor-inWltrating immune cells have frequently been observed in a wide variety of pediatric tumors [103, 125] . Tumor inWltration of lymphocytes is generally associated with a more favorable prognosis and occasionally tumor regression [34, 119] . Another element is the observation that immunosuppressed patients, such as graft recipients, are at higher risk to develop cancer [36, 89] . Initial studies have consistently shown a role of the immune system in the prevention of virally induced cancers in adults such as Kaposi's sarcoma (linked with human herpes virus 8), cervix carcinoma (human papilloma virus), and hepatocellular carcinoma (hepatitis B and C) [96] but also in children with certain lymphomas (induced by the Epstein-Barr virus) [42, 114] . These data suggest that the immune system plays an important role in preventing or controlling malignancy in both adults and children. In spite of the blood-brain-barrier and lack of conventional lymphatics in the brain, there is accumulating evidence that even brain tumors can cause immune activation [10, 72, 99] .
Immunotherapy strategies in pediatric cancer patients
Immunotherapy can be deWned as any approach that seeks to mobilize or manipulate the immune system of a patient for therapeutic beneWt ( Fig. 1) [61, 116] . Clinical experience of immunotherapy in the pediatric oncological setting has been gained in treating hematologic malignancies with allogeneic bone marrow transplantations and infusions of donor lymphocytes to generate graft versus leukemia responses [98] . Other clinical trials for pediatric patients have involved general immunostimulation with cytokines such as IL-2, TNF-, and IFN-, as adjuvant therapies to eradicate minimal residual disease [62, 112, 123, 133] . Immunotherapeutic therapies targeting identiWed tumor-associated antigens are discussed in the following.
Antibodies
The identiWcation of tumor-speciWc cell-surface molecules opened the possibility for antibody-mediated passive immunotherapy. Antibodies (Ab) against tumor-associated antigens can induce complement dependent cytotoxicity (CDC) and Ab-dependent cell-mediated cytotoxicity (ADCC) [70] . Promising pediatric clinical phase I trials have been described using monoclonal Ab against gangliosides, which are highly expressed in neuroblastoma and osteosarcoma [40, 87, 88, 128] . Tumor-speciWc Ab [86, 105] .
Adoptive cellular immunotherapy
Reconstituting or increasing cellular immunity can be achieved through the infusion of tumor-speciWc T cells. Autologous CD4 + or CD8 + T cells can be manipulated ex vivo in various ways to obtain high numbers of clinical grade tumor-speciWc T cells [23] . The therapeutic eVect of infused tumor-speciWc T cells depends on the viability of the cells, their homing to the tumor, and their ability to kill within the tumor microenvironment.
Another aspect is the renewed appreciation of the role of the innate immune system. Immune-mediated tumor lysis is the result of a combined action of adaptive and innate immunity, in which NK cells are important eVector cells. NK cell activation is regulated by a balance between signals mediated through activating receptors such as NKG2D and inhibitory receptors such as killer immunoglobulin-like receptors (KIRs). Upon cellular transformation in tumor cells, MHC class I ligands for inhibitory receptors are often downregulated and ligands for activating NK cell receptors are upregulated on the tumor cell. Together, these events can shift the balance toward NK-mediated tumor-cell killing [78] . Next to the direct cytotoxic eVect on tumor cells, NK cells produce type I interferons that create a proinXammatory tumor microenvironment [106, 113] . Clinical studies on adoptive transfer of NK cells in adults have shown that NK cells can have a role in the treatment of selected malignancies [84] . Adoptive transfer of NK cells in pediatric patients with leukemia is feasible [68] . Ongoing clinical studies further investigate NK cell-mediated immunotherapy for pediatric patients with leukemia or neuroblastoma (http://www.clinicaltrials.gov).
In vivo induction of tumor-speciWc lymphocytes
The advantage of active immunization over adoptive transfer is the possibility of inducing memory T cells that can control tumor relapse [37] . On the basis of the successes of attenuated pathogen vaccines and owing to the initial lack of deWned tumor antigens, the Wrst active immunizations were carried out with whole tumor cells that were previously irradiated or otherwise inactivated [134] . In children, most of the clinical experience using whole tumor cell vaccines is obtained with neuroblastoma patients. In these trials, the neuroblastoma cells are (gene-) modiWed to express various co-stimulatory molecules or cytokines to increase their immunogenicity [9, 16, 107] .
When tumor-associated antigens are identiWed, therapeutic vaccination can involve the administration of the antigen either as a whole recombinant protein or as antigenic peptides presented by HLA class I or class II molecules. One clinical trial reports on using chimeric antigenic peptides encoded by translocated genes expressed in Ewing's sarcoma and rhabdomyosarcoma [26] . Another strategy is the administration of autologous antigen-presenting cells, such as dendritic cells, loaded with deWned tumor antigens or with tumor cell lysates. We reported that clinical grade dendritic cells can be cultured from blood monocytes of pediatric cancer patients [55] . Others have reported that such dendritic cells can induce tumor-speciWc T cells that can cause regression of high-risk malignancies in pediatric patients [19, 29, 30, 43] .
Advances in gene transfer technology have added new possibilities to optimize vaccine preparation [74, 94] . These include transferring genes encoding pro-inXammatory proteins to tumor cells and transferring tumor antigen-encoding genes into professional antigen-presenting cells. Tumor cells can be engineered to express MHC class I and class II, costimulatory molecules, or cytokines, and used as vaccines. Several gene therapy applications to induce antitumor immunity have been reported for pediatric cancer patients in preliminary phase I studies [9] .
Current research also focuses on vaccinating directly with antigen-encoding DNA. Studies in animal models have demonstrated the feasibility of utilizing DNA vaccines to elicit protective cellular and humoral antitumor immune responses [95] . In humans, DNA vaccines are being tested in phase I to III clinical trials for cervical cancer, melanoma, renal cell carcinoma, and prostate cancer [80] . Preliminary results conWrm the safety and immunogenicity of these vaccines. DNA vaccinations have not been studied in pediatric patients. However, Wrst steps are being taken with murine studies showing that DNA-vaccination is potentially eVective to treat neuroblastoma and prevent neuroblastoma metastases [79, 97] .
Tumor-associated antigens
One of the reasons for the paucity of clinical trials of therapeutic anti-cancer vaccination in children is the lack of information about the expression of tumor-speciWc antigens on many pediatric tumors. In the second part of this review we will summarize the current data on the expression of tumor antigens recognized by T cells on a selection of the most common solid pediatric tumors.
Tumor antigens that can be recognized by T lymphocytes are complexes of HLA class I or class II molecules presenting small antigenic peptides. The antigens can be classiWed into four major groups, based on the pattern of expression of the genes encoding the antigenic peptide [14, 90] .
Antigens resulting from mutations or translocations These antigens are encoded by genes that are mutated in tumor cells as compared to the normal cells of the patient; the antigens can therefore be considered strictly tumorspeciWc. The mutations can be point mutations, or translocations, in genes that are expressed ubiquitously. The mutation aVects a coding region of the gene, and antigenic peptides contain mutated residues or straddle the junction of chimeric proteins encoded by translocated genes.
Antigens encoded by cancer-germline genes Cancer-germline genes are expressed in diVerent types of human tumors. They are not expressed in normal tissues with the exception of male germline cells which do not express HLA molecules and therefore cannot present antigenic peptides to T cells [115] . For this reason the antigens encoded by cancer-germline genes are strictly tumorspeciWc.
DiVerentiation antigens
DiVerentiation antigens are encoded by lineage-speciWc genes that are expressed in tumor cells as well as in the normal cells from which the tumor arises. The natural tolerance to these antigens is not complete, and the induction of an immune response against diVerentiation antigens is possible [35] .
Antigens encoded by genes that are overexpressed in tumors
This last group of tumor antigens is encoded by genes that are overexpressed in tumors as compared to normal tissues. Some oncogenes are expressed in normal tissues at a low level and overexpressed in several tumors [17, 38] . Since both diVerentiation antigens and overexpressed antigens are expressed in normal tissues, autoimmunity can be a side eVect when these antigens are used as immunotherapeutic target.
T cell deWned antigens in pediatric solid tumors
For usefulness in immunotherapy, an antigen has to meet two important criteria. It has to be expressed by the tumor of the patient, and it has to be immunogenic. These criteria can be tested with gene/protein expression and lymphocyte recognition/tumor lysis assays (Fig. 2) . For an eVective cellular immune response, the tumor-speciWc antigen must be processed into peptides and presented on HLA molecules. Many tumor-associated antigens and epitopes have been described that are recognized by CD4 + and/or CD8 + T cells. Detailed lists of antigen-encoding genes and of epitopes can be found at http://www.cancerimmunity.org. Tables 1 and 2 summarize T cell deWned antigens on a selection of the most important pediatric solid tumors. The + cells using labeled CD8-Ab and A1/MAGE-3-tetramers. Dot plot of peripheral blood mononuclear cells from a patient who received a vaccine containing MAGE-3.A1 peptides. Twelve percent of the CD8 + cells are tetramer-positive after 2 weeks of in vitro re-stimulation with the MAGE-3.A1 peptide (EVDPIGHLY) [63] . c Chromium release assay using cytotoxic T lymphocyte clone EH-1 B2.C10, which recognizes peptide MAGE-3 168¡176 presented by HLA-A1 molecules. Lysis was tested after 4 h at 37°C, as previously described [12] . Only the HLA- Virus-encoded and artiWcially modiWed epitopes are excluded from this list. Antigens of solid tumors outside the central nervous system are shown in Table 1 , and those of brain tumors in It is important to note that the expression of a given antigen in tumors of adult patients does not guarantee that this antigen is also expressed in the tumor of that same subtype from a pediatric patient. We and others observed signiWcant age-related diVerences in the expression of tumor antigens in glioblastoma samples [57, 92, 100, 120] . For some antigens we noticed important diVerences in the expressions reported by diVerent groups. They can be due to the sensitivity/speciWcity of the techniques used (microarray, RT-PCR and immunohistochemistry), to diVerent antibodies or primer-pairs for the same antigen, and to diVerently chosen cut-oV points. 82] , WT-1 (ongoing clinical trial, http://www.clinicaltrials.gov) and MAGE-A1 (Jacobs et al., manuscript in preparation). Choosing the best antigen in a speciWc immunotherapy trial depends on the individual needs for that study such as the immunogenicity of the antigen, the level of antigen expression by the tumors, the tumor-speciWcity of the antigen, the availability of clinical grade antigenic products, and the HLA-type of the included patients.
Which antigens to choose for pediatric clinical trials?
Mutated tumor antigens are attractive antigens for cancer immunotherapy because of their strict tumor-speciWcity and because of their potential resistance to immunoselection when the mutated gene product plays an important role in the oncogenic process. One drawback is that most point mutations, in contrast to chromosomal translocations, are not shared by tumors from diVerent patients. Examples of chimeric proteins in the pediatric setting are the PAX3-FKHR, EWS-FLI 1, TEL-AML1, and BCR-ABL fusion proteins seen in alveolar rhabdomyosarcoma, Ewing's sarcoma, acute lymphatic leukemia, and chronic myeloid leukemia, respectively [18, 81, 129, 137] . For all four fusion proteins several MHC class I and class II chimeric peptides have been described that induce speciWc T cells and can be considered for immunotherapy [82, [136] [137] [138] .
The other genetic mechanism responsible for tumorspeciWcity of antigens is the aberrant expression in tumor cells of genes that are silent in normal cells. When the antigens are encoded by genes that are expressed in many diVerent tumors they are called 'shared tumor-speciWc antigens'. Most of the shared tumor-speciWc antigens are encoded by cancer-germline genes. Cancer-germline genes such as MAGE, GAGE, or LAGE/NY-ESO-1, are expressed in diVerent types of pediatric tumors (Tables 1,  2 ). Numerous peptides, binding to diVerent HLA class I and HLA class II molecules have been identiWed [15] . Because of their tumor-speciWcity and immunogenic potential, antigens encoded by cancer-germline genes have been one of the main components of antitumor vaccines tested in the clinic during the last decade [115] .
Approximately 20% of all identiWed tumor antigens are encoded by genes that are overexpressed in cancer cells as compared to normal cells. Overexpression in this context means more antigenic peptides presented on MHC molecules at the cell surface, explaining the tumor-speciWcity of the T lymphocytes. As shown in Tables 1 and 2 , many of the identiWed antigens in pediatric solid tumors are classiWed as overexpressed antigens. HER-2, WT-1, and MYCN are the most interesting candidates for immunotherapy since these genes are involved in cell proliferation and their overexpression plays a direct functional role in tumor progression. This role in oncogenesis implies that it is more diYcult for the tumor to escape immune attack through downregulation of antigen expression. The absence of autoimmune tissue damage in cancer patients with HER-2, WT-1, or MYCN speciWc CTLs suggests that these antigens can be safely used as immunotherapeutic target [5, 7, 48] .
With the observation that tumor-speciWc CTL clones derived from melanoma patients could also recognize normal melanocytes it became obvious that natural tolerance to diVerentiation antigens was incomplete [4] . Gp100 and tyrosinase are the only diVerentiation antigens expressed in pediatric tumors for which T cell speciWc peptides are identiWed (Table 2) . Autoimmunity can be a side eVect when diVerentiation antigens are used for vaccination. Since gp100 and tyrosinase are expressed in normal melanocytes, it is possible that pediatric patients will develop vitiligo when these antigens are used in a vaccine [56, 127] .
For safety concern, the target antigens used in pediatric clinical trials should be strictly tumor-speciWc. If such an antigen is not available, the normal tissue expressing the antigen must be dispensable, to avoid serious autoimmune toxicity. Finally, it is probably preferable to use combinations of antigens to decrease the probability of in vivo selection of antigen-negative tumor cells.
Conclusion
Immunotherapy against cancer is a Weld of growing interest. Most therapies are still experimental and focus on adult patients. However, the Wrst immunotherapeutic trials for pediatric cancer patients have been published, and more are ongoing. These novel trials aim at stimulating both humoral and cellular anti-tumor immune responses. The identiWcation of many tumor-associated antigens, including for most pediatric solid tumor types, should facilitate this clinical endeavor. 
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